Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 209.00K | 195.00K | 598.00K | 532.00K | 146.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.00K | 195.00K | 598.00K | 532.00K | 146.00K |
| Cost of Revenue | 6.36M | 5.90M | 13.26M | 18.24M | 12.27M |
| Gross Profit | -6.15M | -5.71M | -12.67M | -17.71M | -12.12M |
| SG&A Expenses | 3.61M | 3.93M | 5.14M | 5.82M | 4.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.98M | 9.83M | 18.40M | 24.06M | 16.62M |
| Operating Income | -9.77M | -9.64M | -17.81M | -23.52M | -16.48M |
| Income Before Tax | -10.97M | -11.87M | -48.12M | -22.44M | -15.14M |
| Income Tax Expenses | 6.00K | 7.00K | 12.00K | 14.00K | 17.00K |
| Earnings from Continuing Operations | -10.98M | -11.87M | -48.13M | -22.45M | -15.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.98M | -11.87M | -48.13M | -22.45M | -15.16M |
| EBIT | -9.77M | -9.64M | -17.81M | -23.52M | -16.48M |
| EBITDA | -9.62M | -9.60M | -17.66M | -23.39M | -16.39M |
| EPS Basic | -0.17 | -0.18 | -0.74 | -0.35 | -0.25 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.16 | -0.22 | -0.15 |
| EPS Diluted | -0.17 | -0.18 | -0.74 | -0.35 | -0.25 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.16 | -0.22 | -0.15 |
| Average Basic Shares Outstanding | 65.51M | 65.46M | 65.46M | 64.01M | 61.53M |
| Average Diluted Shares Outstanding | 65.51M | 65.46M | 65.46M | 64.01M | 61.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |